Protagonist Therapeutics Inc (PTGX)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 97,249 | 186,727 | 125,744 | 123,665 | 117,358 |
| Short-term investments | US$ in thousands | 321,664 | 154,890 | 111,611 | 203,235 | 188,451 |
| Total current liabilities | US$ in thousands | 47,398 | 21,274 | 31,179 | 44,016 | 40,241 |
| Cash ratio | 8.84 | 16.06 | 7.61 | 7.43 | 7.60 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($97,249K
+ $321,664K)
÷ $47,398K
= 8.84
The cash ratio for Protagonist Therapeutics Inc has shown consistency over the years, ranging from 7.43 to 16.06. This ratio indicates the company's ability to cover its short-term liabilities with its cash and cash equivalents. In December 31, 2023, the cash ratio significantly increased to 16.06, reflecting a strong liquidity position at that time. However, it returned to a more typical range in the following years. Overall, the company maintains a healthy level of cash reserves compared to its current liabilities, which suggests a good ability to meet its short-term financial obligations.
Peer comparison
Dec 31, 2024